GLPwatch
Papers (10376)
Page 89 of 173, ranked by citation count.
- Tirzepatide-Induced Rapid Weight Loss-Related Thyrotoxicosis.
- Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data.
- Diabetic Ketoacidosis in a Patient With Type I Diabetes Treated With a Closed-Loop Sensor-Augmented Insulin Infusion System.
- Absorption, distribution, metabolism, and excretion of tirzepatide in humans, rats, and monkeys.
- Unmet needs in current clinical practice for insulinoma: Lessons from nationwide studies in Japan.
- A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients.
- Glucagon-like peptide-1 receptor activation stimulates PKA-mediated phosphorylation of Raptor and this contributes to the weight loss effect of liraglutide.
- Liraglutide Improves Estimated Glomerular Filtration Rate Slopes in Patients with Chronic Kidney Disease and Type 2 Diabetes: A 7-Year Retrospective Analysis.
- Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide.
- Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes.
- Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study.
- Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review.
- Mouse insulin cells expressing an inducible RIPCre transgene are functionally impaired.
- Glycogen synthesis kinase-3β involves in the analgesic effect of liraglutide on diabetic neuropathic pain.
- Characterization of the use of liraglutide for glycemic control in healthy and Type 1 diabetes mellitus suffering dogs.
- Comparison between liraglutide alone and liraglutide in combination with insulin on osteoporotic rats and their effect on bone mineral density.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Maladaptive Eating Behaviours, Generalised Anxiety Disorder and Depression Severity: A Comparative Study between Adult Women with Overweight, Obesity, and Normal Body Mass Index Range.
- Development of thiolated poly(acrylic acid) microparticles for the nasal administration of exenatide.
- Liraglutide combined with intense lifestyle modification in the management of obesity in adolescents.
- Anaphylaxis to Long-Acting Release Exenatide.
- The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus.
- Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects.
- Novel fatty acid chain modified GLP-1 derivatives with prolonged in vivo glucose-lowering ability and balanced glucoregulatory activity.
- The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta-regression analysis of randomized controlled trials.
- Sustained exenatide delivery via intracapsular microspheres for improved survival and function of microencapsulated porcine islets.
- A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats.
- Pharmacological treatment of obesity in adults in Norway 2004-2022.
- Editorial: Global Obesity Rates Continue to Rise with Challenges for New Drug Treatments Including GLP-1 Receptor Agonists.
- GLP-1RA in the Real World: 1-year Compliance and Outcomes of Semaglutide use in Patients With or Without Previous History of Bariatric Surgery.
- Effect of Glucagon-Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis.
- Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.).
- Dulaglutide accelerates diabetic wound healing by suppressing Nrf2-dependent ferroptosis in diabetic mice.
- Lipidomic Analysis Reveals the Protection Mechanism of GLP-1 Analogue Dulaglutide on High-Fat Diet-Induced Chronic Kidney Disease in Mice.
- In vitro comparison of various antioxidants and flavonoids from Rooibos as beta cell protectants against lipotoxicity and oxidative stress-induced cell death.
- The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain.
- Construction of human pluripotent stem cell-derived testicular organoids and their use as humanized testis models for evaluating the effects of semaglutide.
- A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?
- Risk and Benefit Profile of Dulaglutide in Established Therapeutic Indication.
- A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease.
- Semaglutide and Other GLP-1 Agonists: A Boon for the Arthroplasty Industry?
- Determination of the Plasma Protein Binding of Liraglutide Using the EScalate<sup>*</sup> Equilibrium Shift Assay.
- The effect of glucagon-like peptide-1 agonists on ocular parameters in idiopathic intracranial hypertension patients: a retrospective study.
- Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial.
- Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
- Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs.
- Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment.
- Triple Agonism Based Therapies for Obesity.
- Impact of semaglutide on lipid profiles in overweight and obese non-diabetic adults: A systematic review and meta-analysis of randomized controlled trials.
- Role of exendin-4 in the Gila monster: Further lessons regarding human oral glucagon-like peptide-1 therapy?
- Managing bile acid diarrhea: aspects of contention.
- A Specific HPLC Method to Determine Residual HEPES in [<sup>68</sup>Ga]Ga-Radiopharmaceuticals: Development and Validation.
- Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity.
- Exenatide as a novel weight loss modality in patients without diabetes.
- Case report of the successful use of semaglutide to achieve target BMI prior to renal transplant in two patients with end-stage-kidney-disease.
- Glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist tirzepatide promotes branched chain amino acid catabolism to prevent myocardial infarction in non-diabetic mice.
- [Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus].
- Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial).
- Glucagon-Like Peptide-1 Receptor Agonists and Age-Related Macular Degeneration.
- Mitigation of Hearing Damage After Repeated Blast Exposures in Animal Model of Chinchilla.